knowledge -WSS

knowledge

author：fashion 2025-09-28 21:16:04 - browse：62

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： ARCH Venture Partners tops STAT's 2023 biotech VC rankings

WSS

Sanofi seeks simpler, safer CRISPR sickle cell cure

The (many) problems with a new study criticizing cancer screening

A public scorecard can help hold safety

Illumina names Agilent executive as new CEO

Covid hospitalizations on the rise, Humana says

Sanofi seeks simpler, safer CRISPR sickle cell cure

leisure time

knowledge

hotspot

Jerome Adams on the need for new antivirals for Covid

Google and Epic fight stronger regulation of AI in health care

Guidelines to prevent youth baseball injuries need more muscle

Doctors find melanoma drugs effective against rare brain cancer

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Snackable artificial intelligence, expert AI, and the pharma industry

Tori Bowie and the unacceptable rates of Black maternal death

AstraZeneca chief proposes a novel edit to the drug pricing bill

Bright Health sells Medicare Advantage business to Molina

Biden tests positive for Covid

knowledge

Crinetics acromegaly drug succeeds in late

Listen: Wegovy in the brain & pivotal Alzheimer's data

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

What drug price negotiations mean for Medicare Part D

In early work, researchers turn to CRISPR to treat Alzheimer's

explore

Wikipedia

explore

entertainment